Therapeutic potential of dendritic-based vaccines

Bibliography

• FEARON DT, LOCKSLEY RM: The instructive role of innate immunity in the acquired immune response. Science (1996) 272:50–53.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245–252.
   PubMed Web of Science ®Google Scholar
• CELLA M, SALLUSTO F, LANZAVECCHIA A: Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. (1997) 9:10–16.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM, COHN ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. J. Exp. Med. (1973) 137:1142–1162.
   PubMed Web of Science ®Google Scholar
• ••Initial description of the dendritic cell.
   Google Scholar
• WRIGHT-BROWNE V, MCCLAIN KL, TALPAZ M, ORDONEZ N, ESTROV Z: Physiology and pathophysi-ology of dendritic cells. Hum. Pathol. (1997) 28:563–579.
   PubMed Web of Science ®Google Scholar
• PALUCKA K, BANCHEREAU J: Dendritic cells: a link between innate and adaptive immunity. J. Clin. Immunol. (1999) 19:12–25.
   PubMed Web of Science ®Google Scholar
• CAUX C, VANBERVLIET B, MASSACRIER C et al: CD34+hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J. Exp. Med. (1996) 184:695–706.
   PubMed Web of Science ®Google Scholar
• CAUX C, MASSACRIER C, VANBERVLIET B et al.: CD34+hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood (1997) 90:1458–1470.
   Google Scholar
• RISSOAN MC, SOUMELIS V, KADOWAKI N et al.: Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 283:1183–1186.
   PubMed Web of Science ®Google Scholar
• WATTS C: Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. (1997) 15:821–850.
   PubMed Web of Science ®Google Scholar
• TULP A, VERWOERD D, DOBBERSTEIN B, PLOEGH HL,PLETERS J: Isolation and characterization of the intracellular MHC class II compartment. Nature (1994) 369:120–126.
   PubMed Web of Science ®Google Scholar
• JONDAL M, SCHIRMBECK R, REIMANN J: MHC class I-restricted CTL responses to exogenous antigens. Immunity (1996) 5:295–302.
   PubMed Web of Science ®Google Scholar
• ALBERT ML, PEARCE SFA, FRANCISCO LM et al.: Immaturedendritic cells phagocytose apoptotic cells via avI35 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. (1998) 188:1359–1368.
   PubMed Web of Science ®Google Scholar
• •This paper was one of the first to delineate the mechanism by which dendritic cells process and present exogenous antigen via the MHC class I pathway.
   Google Scholar
• BENNETT SR, CARBONE FR, KARAMALIS F, MILLER JF, HEATH WR: Induction of a CD8+ cytotoxic T lympho-cyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Merl. (1997) 186:65–70.
   PubMed Web of Science ®Google Scholar
• •Important study describing the phenomenon of cross-priming.
   Google Scholar
• ALBERT ML, SAUTER B, BHARDWAJ N: Dendritic cellsacquire antigen from apoptotic cells and induce class I restricted CTLs. Nature (1998) 392:86–89.
   PubMed Web of Science ®Google Scholar
• ROAKE JA, RAO AS, MORRIS PJ et al.: Dendritic cell lossfrom nonlymphoid tissues after systemic administra-tion of lipopolysaccharide, tumor necrosis factor, and interleukin 1.j Exp. Med. (1995) 181:2237–2247.
   Google Scholar
• SALLUSTO F, CELLA M, DANIELI C, LANZAVECCHIA A:Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J. Exp. Merl. (1995) 182:389–400.
   PubMed Web of Science ®Google Scholar
• PIERRE P, TURLEY SJ, GATTI E et al.: Developmentalregulation of MHC class II transport in mouse dendritic cells. Nature (1997) 388:787–792.
   PubMed Web of Science ®Google Scholar
• CELLA M, ENGERING A, PINET V, PIETERS J, LANZAVEC-CHIA A: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature (1997) 388:782–787.
   PubMed Web of Science ®Google Scholar
• RESCIGNO M, CITTERIO S, THERY C et al.: Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc. NMI Acad. Sci. USA (1998) 95:5229–5234.
   PubMed Web of Science ®Google Scholar
• KHANNA R: Tumour surveillance: missing peptidesand MHC molecules. Immunol. Cell Biol. (1998) 76:20–26.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP, ESQUIVEL F, KAWAKAMI Y et al.: Identifica-tion of human cancers deficient in antigen processing. J. Exp. Med. (1993) 177:265–272.
   PubMed Web of Science ®Google Scholar
• •This research first described a key way in which tumours evade immune surveillance.
   Google Scholar
• BODMER WF, BROWNING MJ, KRAUSA P et al.: Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY Acad. Sci. (1993) 690:42–49.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ NC, LOZIER A, FLAMENT C et al.: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. (1999) 5:405–411.
   PubMed Web of Science ®Google Scholar
• THEOBALD M, BIGGS J, DITTMER D, LEVINE AJ, SHERMAN LA: Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA (1995) 92:11993–11997.
   PubMed Web of Science ®Google Scholar
• WOLFEL T, HAUER M, SCHNEIDER J et al.: A pl6INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 269:1281–1284.
   PubMed Web of Science ®Google Scholar
• FUCHS EJ, BEDI A, JONES RJ, HESS AD: Cytotoxic T cellsovercome BCR-ABL-mediated resistance to apoptosis. Cancer Res. (1995) 55:463–466.
   PubMed Web of Science ®Google Scholar
• CAMPBELL MJ, ESSERMAN L, BYARS NE, ALLISON AC, LEVY R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol (1990) 145:1029–1036.
   Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643–1647.
   Google Scholar
• ••Identification of the first tumour-associated antigen usingcytotoxic T-cells.
   Google Scholar
• BOLL P, WILDMANN C, SENSI ML eta].: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity (1995) 2:167–175.
   Google Scholar
• VAN DEN EYNDE B, PEETERS 0, DE BACKER 0 et al.: A new family of gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Merl. (1995) 182:689–698.
   Google Scholar
• BRICHARD V, VAN PEL A, WOLFEL T eta].: The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanoma. J. Exp. Merl. (1993) 178:489–495.
   Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al.: Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA (1994) 91:3515–3519.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al.: Identifi-cation of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA (1994) 91:6458–6462.
   PubMed Web of Science ®Google Scholar
• •Benchmark report improving and simplifying the technique necessary to use reactive T-cells in the identification of antigens with clinical relevance.
   Google Scholar
• KAWAKAMI Y, ROBBINS PF, WANG RF, ROSENBERG SA: Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer. Prin. Prac. Oncol. (1996) 10:1–20.
   Google Scholar
• CHEEVER MA, DISIS ML, BERNHARD H et al.: Immunity to oncogenic proteins. Immunol. Rev. (1995) 145:33–59.
   PubMed Web of Science ®Google Scholar
• AMBINDER RF, LEMAS MV, MOORE S et al: Epstein-Barr virus and lymphoma. Cancer Treat. Res. (1999) 99:27–45.
   PubMedGoogle Scholar
• CHISARI FV, FERRARI C: Hepatitis B virus immuno-pathogenesis. Annu. Rev. Immunol. (1995) 13:29–60.
   PubMed Web of Science ®Google Scholar
• BEAUDENON S, KREMSDORF D, CROISSANT 0 et al: Anovel type of human papillomavirus associated with genital neoplasias. Nature (1986) 321:246–249.
   PubMed Web of Science ®Google Scholar
• KNIGHT SC: Dendritic cells as initiators of tumour immunity. Immunol Today (1995) 16:547.
   PubMedGoogle Scholar
• NAIR SK, SNYDER D, ROUSE BT, GILBOA E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer (1997) 70:706–715.
   PubMed Web of Science ®Google Scholar
• NAIR SK, BOCZKOWSKI D, SNYDER D, GILBOA E: Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. (1997) 27:589–597.
   PubMed Web of Science ®Google Scholar
• BOCZKOWSKI D, NAIR SK, SNYDER D, GILBOA E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. (1996) 184:465–472.
   PubMed Web of Science ®Google Scholar
• •A promising approach to overcoming the need for large amounts of tumour material in order to generate antigen for dendritic cell-based vaccines.
   Google Scholar
• GONG J, CHEN D, KASHIWABA M, KUFE D: Induction ofantitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. (1997) 3:558–561.
   PubMed Web of Science ®Google Scholar
• LESPAGNARD L, METTENS P, VERHEYDEN AM et al: Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer (1998) 76:250–258.
   PubMed Web of Science ®Google Scholar
• CHOUDHURY A, GAJEWSKI JL, LIANG JC et al: Use ofleukemic dendritic cells for the generation of antileu-kemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood (1997) 89:1133–1142.
   PubMed Web of Science ®Google Scholar
• CHOUDHURY A, HANG JC, THOMAS EK et al.: Dendriticcells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood (1999) 93:780–786.
   PubMed Web of Science ®Google Scholar
• CELLUZZI CM, MAYORDOMO JI, STORKUS WJ, LOTZE MT,FALO, JR, LD: Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. (1996) 183:283–287.
   PubMed Web of Science ®Google Scholar
• PORGADOR A, GILBOA E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. (1995) 182:255–260.
   PubMed Web of Science ®Google Scholar
• OSSEVOORT MA, FELTKAMP MC, VAN VEEN KJ, MELIEF CJ, KAST WM: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus Type 16-induced tumor. J. Immunother. Emphasis Tumour Immunol. (1995) 18:86–94.
   PubMed Web of Science ®Google Scholar
• MAYORDOMO JI, ZORINA T, STORKUS WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. (1995) 1:1297–1302.
   PubMed Web of Science ®Google Scholar
• •Using dendritic cells and simple exogenous addition of tumour peptides, mice were protected against a subsequent lethal tumour challenge.
   Google Scholar
• MAYORDOMO JI, LOFTUS DJ, SAKAMOTO H et al.: Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines. J. Exp. Med. (1996) 183:1357–1365.
   PubMed Web of Science ®Google Scholar
• PAGLIA P, CHIODONI C, RODOLFO M, COLOMBO MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. (1996) 183:317–322.
   PubMed Web of Science ®Google Scholar
• SPECHT JM, WANG G, DO MT et al.: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. (1997) 186:1213–1221.
   PubMed Web of Science ®Google Scholar
• SONG W, KONG HL, CARPENTER H et al.: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protec-tive and therapeutic antitumor immunity. J. Exp. Med. (1997), 186:1247–1256.
   PubMed Web of Science ®Google Scholar
• BUTTERFIELD LH, JILANI SM, CHAKRABORTY NG et al.: Generation of melanoma-specific cytotoxic T lympho-cytes by dendritic cells transduced with a MART-1 adenovirus. j Immunol. (1998) 161:5607–5613.
   PubMed Web of Science ®Google Scholar
• KIM CJ, CORMIER J, RODEN M et al.: Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann. Surg. Oncol. (1998) 5:64–76.
   PubMed Web of Science ®Google Scholar
• LYMAN SD, WILLIAMS DE: Biology and potential clinical applications of flt3 ligand. Curr. Opin. Hematol. (1995) 2:177–181.
   PubMedGoogle Scholar
• MARASKOVSKY E, BRASEL K, TEEPE M et al.: Dramatic increase in the numbers of functionally mature dendritic cells in F1t3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. (1996) 184:1953–1962.
   PubMed Web of Science ®Google Scholar
• •First description of the dramatic effect of F1t3L on the dendritic cell population in vivo.
   Google Scholar
• LYNCH DH: Induction of dendritic cells (DC) by F1t3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Grit. Rev. Immunol. (1998) 18:99–107.
   PubMed Web of Science ®Google Scholar
• CHEN K, BRAUN S, LYMAN S et al.: Antitumor activityand immunotherapeutic properties of F1t3-ligand in a murine breast cancer model. Cancer Res. (1997) 57:3511–3516.
   PubMed Web of Science ®Google Scholar
• KUNDU SK, ENGLEMAN E, BENIKE C et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous
   Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. (1996) 2:52–58.
   PubMed Web of Science ®Google Scholar
• •First clinical trial using antigen-loaded dendritic cells.
   Google Scholar
• REICHARDT VL, OKADA CY, LISO A et al.: Idiotypevaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood (1999) 93:2411–2419.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination ofmelanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Merl. (1998) 4:328–332.
   PubMed Web of Science ®Google Scholar
• •Clear demonstration of the potential therapeutic benefit of a dendritic cell-based vaccine in a human experimental clinical trial.
   Google Scholar
• MORSE, MA, COLEMAN, RE, AKABANI, G, NIEHAUS, N, COLEMAN, D LYERLY, HK: Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. (1999) 59:56–58.
   PubMed Web of Science ®Google Scholar
• HOLTL L, RIESER C, PAPESH C et al: CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer [letter]. Lancet (1998) 352:1358.
   PubMed Web of Science ®Google Scholar
• HOLTL L, RIESER C, PAPESH C et al.: Cellular andhumoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. (1999) 161:777–782.
   PubMed Web of Science ®Google Scholar
• MURPHY G, TJOA B, RAGDE H, KENNY G, BOYNTON A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 29:371–380.
   PubMed Web of Science ®Google Scholar
• TJOA BA, SIMMONS SJ, BOWES VA et al.: Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 36:39–44.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate (1999) 38:73–78.
   PubMed Web of Science ®Google Scholar
• •A promising therapeutic impact is shown in advanced cancer patients for whom no other effective treatment options exists.
   Google Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al.: Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 39:54–59.
   PubMed Web of Science ®Google Scholar
• SIMMONS SJ, TJOA BA, ELGAMAL A et al: GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial. (1999). In Press.
   Google Scholar
• LOTZE MT: Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann. Surg. (1997) 226:1–5.
   PubMed Web of Science ®Google Scholar
• GABRILOVICH DI, CORAK J, CIERNIK IF, KAVANAUGH D, CARBONE DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin.Cancer Res. (1997) 3:483–490.
   PubMed Web of Science ®Google Scholar
• TROY AJ, SUMMERS KL, DAVIDSON PJ, ATKINSON CH, HART DN: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. (1998) 4:585–593.
   PubMed Web of Science ®Google Scholar
• GABRILOVICH DI, CHEN HL, GIRGIS KR etal.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Merl. (1996) 2:1096–1103.
   Google Scholar
• LARGE MK, KITTLESEN DJ, HAHN YS: Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. (1999) 162:931–938.
   PubMed Web of Science ®Google Scholar
• GOLDMAN DL, FRIES BC, FRANZOT SP, MONTELLA L, CASADEVALL A: Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc. Natl. Acad. Sci. USA (1998) 95:14967–14972.
   PubMed Web of Science ®Google Scholar